This is a 2 part study of the safety, pharmacokinetics and pharmacodynamics of MK-6325 in HCV-infected participants. Part I of the study will be for Genotype (GT) 1 HCV-infected participants who will be randomized to receive either MK-6325 or placebo. If the drug is shown to be safe and efficacious in Part I, Part II will enroll GT 3 HCV-infected participants who will be randomized to receive either MK-6325 or placebo.

Start Date01 May 2011

Sponsor / Collaborator

Merck Sharp & Dohme Corp.

100 Clinical Results associated with MK-6325

100 Translational Medicine associated with MK-6325

100 Patents (Medical) associated with MK-6325

Literatures (Medical) associated with MK-6325

01 Jan 2019·Life SciencesQ3 · MEDICINE

A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches

Q3 · MEDICINE

Article

Author: Elshemey, Wael M ; Ezat, Ahmed A

AIMSTo investigate the efficacy of Direct Acting Antivirals (DAAs) in the treatment of different Hepatitis C Virus (HCV) genotypes.MAIN METHODSHomology modeling is used to predict the 3D structures of different genotypes while molecular docking is employed to predict genotype - drug interactions (Binding Mode) and binding free energy (Docking Score).KEY FINDINGSSimeprevir (TMC435) and to a lesser degree MK6325 are the best drugs among the studied drugs. The predicted affinity of drugs against genotype 1a is always better than other genotypes. P2-P4 macrocyclic drugs show better performance against genotypes 2, 3 and 5. Macrocyclic drugs are better than linear drugs.SIGNIFICANCEHCV is one of the major health problems worldwide. Until the discovery of DAAs, HCV treatment faced many failures. DAAs target key functional machines of the virus life cycle and shut it down. NS3/4A protease is an important target and several drugs have been designed to inhibit its functions. There are several NS3/4A protease drugs approved by Food and Drug Administration (FDA). Unfortunately, the virus exhibits resistance against these drugs. This study is significant in elucidating that no one drug is able to treat different genotypes with the same efficiency. Therefore, treatment should be prescribed based on the HCV genotype.

20 Mar 2015·Organic LettersQ1 · CHEMISTRY

Synthesis of Bis-Macrocyclic HCV Protease Inhibitor MK-6325 via Intramolecular sp²–sp³ Suzuki–Miyaura Coupling and Ring Closing Metathesis

Q1 · CHEMISTRY

Article

Author: Song, Zhiguo Jake ; Belyk, Kevin ; Alam, Mahbub ; Tan, Lushi ; Journet, Michel ; Stewart, Gavin W. ; Kosjek, Birgit ; Balsells, Jaume ; Wise, Christopher ; Baxter, Carl A. ; Li, Hongmei ; Chen, Cheng-yi ; Scott, Jeremy P.

A practical asymmetric synthesis of the complex fused bis-macrocyclic HCV protease inhibitor MK-6325 (1) is described. Through the combination of a high yielding and low catalyst loading ring-closing metathesis (RCM) to forge the 15-membered macrocycle with an intramolecular sp(2)-sp(3) Suzuki-Miyaura cross-coupling to append the 18-membered macrocycle, multikilogram access to the unique and challenging architecture of MK-6325 (1) has been achieved.

100 Deals associated with MK-6325

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15249

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis C	Preclinical	MD	Merck GmbH	-
Hepatitis C	Discovery	DE	Merck GmbH	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis